Alamar Biosciences, Inc. (NASDAQ:ALMR) Short Interest Update

Alamar Biosciences, Inc. (NASDAQ:ALMR) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totaling 1,153,031 shares, an increase of ∞ from the April 15th total of 0 shares. Currently, 1.7% of the shares of the company are sold short. Based on an average daily trading volume, of 776,628 shares, the days-to-cover ratio is currently 1.5 days.

Insider Buying and Selling

In other Alamar Biosciences news, major shareholder Innovation Fund Gp Illumina II bought 235,294 shares of the business’s stock in a transaction on Monday, April 20th. The shares were purchased at an average price of $17.00 per share, with a total value of $3,999,998.00. Following the purchase, the insider directly owned 507,076 shares of the company’s stock, valued at approximately $8,620,292. The trade was a 86.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Nicholas Naclerio bought 235,294 shares of the business’s stock in a transaction that occurred on Monday, April 20th. The shares were acquired at an average cost of $17.00 per share, with a total value of $3,999,998.00. Following the completion of the purchase, the director owned 507,076 shares of the company’s stock, valued at approximately $8,620,292. The trade was a 86.57% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Alamar Biosciences Stock Down 3.2%

ALMR stock opened at $20.86 on Tuesday. Alamar Biosciences has a 1 year low of $20.40 and a 1 year high of $27.20.

Alamar Biosciences (NASDAQ:ALMR) last posted its quarterly earnings data on Friday, May 8th. The company reported ($1.74) earnings per share (EPS) for the quarter. The firm had revenue of $26.04 million for the quarter.

Analyst Ratings Changes

Several equities analysts recently commented on ALMR shares. Wall Street Zen upgraded Alamar Biosciences to a “hold” rating in a research report on Saturday, April 25th. TD Cowen initiated coverage on Alamar Biosciences in a report on Tuesday, May 12th. They set a “buy” rating and a $30.00 price objective for the company. Zacks Research upgraded shares of Alamar Biosciences to a “hold” rating in a research report on Wednesday, May 13th. Stifel Nicolaus assumed coverage on Alamar Biosciences in a research note on Tuesday, May 12th. They issued a “buy” rating and a $28.00 price objective on the stock. Finally, JPMorgan Chase & Co. assumed coverage on Alamar Biosciences in a research note on Tuesday, May 12th. They issued an “overweight” rating and a $30.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $30.00.

Alamar Biosciences Company Profile

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.